PULM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pulmatrix Inc. is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, technical indicators are bearish, and there are no strong positive catalysts to justify an immediate investment. The merger news and funding are positive developments, but the lack of profitability and poor growth trends make this stock unsuitable for the investor's profile.
The technical indicators for PULM are bearish. The MACD is negatively expanding, the RSI is neutral at 21.124, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support and resistance levels, with the pivot at 2.004 and the pre-market price at 1.53, which is below S1 (1.591).
The company has announced a merger with Eos Senolytix, which could create a stronger entity focused on health span enhancement. Additionally, Pulmatrix has secured $19 million in funding to advance its clinical candidate PTc-2105.
The market sentiment is neutral, with no significant insider or hedge fund activity. Technical indicators are bearish, and the stock has a high probability of further short-term declines.
In Q4 2025, Pulmatrix's revenue dropped to $0 (-100% YoY), net income fell to -$928,000 (-53.27% YoY), and EPS decreased to -0.25 (-53.70% YoY). Gross margin also dropped to 0 (-100% YoY), indicating severe financial struggles.
No analyst rating or price target changes are available for PULM.
